Commissioned Luxturna Treatment Centres
Where to refer a patient who has confirmed biallelic RPE65 mutations.
Four centres across the UK have been commissioned by NHS England to administer Luxturna® (voretigene neparvovec) to eligible patients. These centres can be consulted to discuss your RPE65-mutation-associated IRD patients and their potential eligibility for Luxturna.
Please contact us for more information.
IRD, inherited retinal dystrophy; RPE, retinal pigment epithelium.
Indication: Luxturna is indicated for the treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.1
- Luxturna SmPC, 2020.